Extended analysis of benchmark datasets for Agilent two-color microarrays

door Kerr, Kathleen F
Gepubliceerd in 2007

Comments on the analysis of unbalanced microarray data

door Kerr, Kathleen F.
Gepubliceerd in 2009

Joint Modeling, Covariate Adjustment, and Interaction: Contrasting Notions in Risk Prediction Models and Risk Prediction Performance

door Kerr, Kathleen F., Pepe, Margaret S.
Gepubliceerd in 2011

A Comparison of Two Classes of Methods for Estimating False Discovery Rates in Microarray Studies

door Hansen, Emily, Kerr, Kathleen F.
Gepubliceerd in 2012

First things first: Risk model performance metrics should reflect the clinical application

door Kerr, Kathleen F., Janes, Holly
Gepubliceerd in Stat Med (2017)

Empirical evaluation of data transformations and ranking statistics for microarray analysis

door Qin, Li-Xuan, Kerr, Kathleen F.
Gepubliceerd in 2004

Further Insight Into the Incremental Value of New Markers: The Interpretation of Performance Measures and the Importance of Clinical Context

door Kerr, Kathleen F., Bansal, Aasthaa, Pepe, Margaret S.
Gepubliceerd in 2012

Comparisons of cancer staging systems should be based on overall performance in the population

door Kerr, Kathleen F, LeBlanc, Michael, Janes, Holly
Gepubliceerd in Clin Trials (2017)

Using ordinal outcomes to construct and select biomarker combinations for single-level prediction

door Meisner, Allison, Parikh, Chirag R., Kerr, Kathleen F.
Gepubliceerd in Diagn Progn Res (2018)

The Importance of Uncertainty and Opt In vs. Opt Out: Best Practices for Decision Curve Analysis()

door Kerr, Kathleen F., Marsh, Tracey L., Janes, Holly
Gepubliceerd in Med Decis Making (2019)

Testing for improvement in prediction model performance

door Pepe, Margaret Sullivan, Kerr, Kathleen F., Longton, Gary, Wang, Zheyu
Gepubliceerd in 2013

Assessing the Clinical Impact of Risk Prediction Models With Decision Curves: Guidance for Correct Interpretation and Appropriate Use

door Kerr, Kathleen F., Brown, Marshall D., Zhu, Kehao, Janes, Holly
Gepubliceerd in J Clin Oncol (2016)

Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification

door Ioannou, George N., Green, Pamela, Kerr, Kathleen F., Berry, Kristin
Gepubliceerd in J Hepatol (2019)

Assessing the Clinical Impact of Risk Models for Opting Out of Treatment

door Kerr, Kathleen F., Brown, Marshall D., Marsh, Tracey L., Janes, Holly
Gepubliceerd in Med Decis Making (2019)

Evaluating the Incremental Value of New Biomarkers With Integrated Discrimination Improvement

door Kerr, Kathleen F., McClelland, Robyn L., Brown, Elizabeth R., Lumley, Thomas
Gepubliceerd in 2011

Developing Risk Prediction Models for Kidney Injury and Assessing Incremental Value for Novel Biomarkers

door Kerr, Kathleen F., Meisner, Allison, Thiessen-Philbrook, Heather, Coca, Steven G., Parikh, Chirag R.
Gepubliceerd in 2014

RiGoR: reporting guidelines to address common sources of bias in risk model development

door Kerr, Kathleen F, Meisner, Allison, Thiessen-Philbrook, Heather, Coca, Steven G, Parikh, Chirag R
Gepubliceerd in Biomark Res (2015)

Methodological issues in current practice may lead to bias in the development of biomarker combinations for predicting acute kidney injury

door Meisner, Allison, Kerr, Kathleen F., Thiessen-Philbrook, Heather, Coca, Steven G., Parikh, Chirag R.
Gepubliceerd in Kidney Int (2016)

BioPETsurv: Methodology and open source software to evaluate biomarkers for prognostic enrichment of time-to-event clinical trials

door Cheng, Si, Kerr, Kathleen F., Thiessen-Philbrook, Heather, Coca, Steven G., Parikh, Chirag R.
Gepubliceerd in PLoS One (2020)

Net Reclassification Indices for Evaluating Risk-Prediction Instruments: A Critical Review

door Kerr, Kathleen F., Wang, Zheyu, Janes, Holly, McClelland, Robyn L., Psaty, Bruce M., Pepe, Margaret S.
Gepubliceerd in 2014